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          S. aureus   is a leading cause of blood-
stream, skin, soft tissue, and lower re-
spiratory tract infections worldwide (  1  ). 
In developed countries such as the Uni-
ted States, resistance to      -lactam anti-
biotics in MRSA is a major problem in 
hospitals and other healthcare settings. 
In these settings,   S. aureus   infections are 
primarily caused by MRSA and typi-
cally occur in individuals with risk fac-
tors for disease, such as those who are 
immunocompromised or have had sur-
gery. Notably, the incidence rate of all 
invasive MRSA infections, including 
those outside of hospitals, is high com-
pared with other bacterial pathogens 
(31.3 per 100,000 individuals), and 20% 
of these infections result in death (  2  ). 
Although bacteremia is the most prev-
alent condition during invasive disease 
caused by MRSA, pneumonia ranks 
second and occurs in     13.3% of all in-
vasive infections (  2  ). 
  In contrast to   S. aureus   infections 
acquired in healthcare settings, com-
munity-associated   S. aureus   infections, 
which in the United States are also caused 
primarily by MRSA, occur in other-
wise healthy individuals. The majority 
of community-associated MRSA (CA-
MRSA) infections are treatable infec-
tions of skin and soft tissue (  3  ), but 
some infections lead to severe invasive 
disease (  4  ). CA-MRSA was fi  rst reported 
in the late 1990s, when pneumonia was 
the third most prevalent syndrome, oc-
curring in 13.5% of infected children (  5  ). 
The most prevalent CA-MRSA isolate, 
known as USA300, accounts for up to 
97% of all CA-MRSA infections (  6  ). 
  Past eff  orts to generate an eff  ective 
vaccine against   S. aureus   have thus far 
been unsuccessful. A new report by 
Wardenburg and Schneewind on page 
  287   in this issue (  7  ) shows that immu-
nization with the   S. aureus   virulence 
factor Hla protects mice from an other-
wise lethal   S. aureus   infection. 
  Virulence factors and immune evasion 
    S. aureus   encodes a remarkable repertoire 
of virulence factors. These molecules 
promote host colonization, facilitate 
evasion of the human innate immune 
system, and alter immune responses (for 
review see reference   8  ). For the pur-
poses of this commentary, we will limit 
our discussion to a few   S. aureus   surface 
molecules, some of which have been 
used previously as vaccine targets. 
  Human neutrophils are a primary 
cellular defense against bacterial infec-
tions. Previous studies have shown that 
host opsonins, such as serum comple-
ment and antibody, play a major role in 
the phagocytosis of   S. aureus   by neu-
trophils (  9  –  11  ).   S. aureus   makes several 
proteins, including protein A, serotype 5 
or 8 capsular polysaccharide (CP5 or 
CP8), and clumping factor A (ClfA), 
which inhibit phagocytosis (  12  –  14  ). 
But despite the bacteria  ’  s eff  orts to evade 
neutrophils, normal human serum con-
tains a suffi   cient number of opsonins to 
promote their rapid uptake by these 
cells (  15  ). The majority of clinical iso-
lates, including USA300, encode ClfA 
and CP5 or CP8 (  14  ). Because anti-
bodies specifi  c for CP5 or CP8 enhance 
phagocytosis, CP5 and CP8 have been 
evaluated extensively as vaccine antigens 
(  16  –  18  ). In the end, however,   S. aureus   
vaccines designed to enhance bacterial 
uptake have had limited success. 
  One possible reason for this out-
come is the lack of correlation between 
uptake of the bacteria by neutrophils and 
their subsequent destruction. For in-
stance, the most prominent CA-MRSA 
isolates survive relatively well inside 
neutrophils, probably in part because of 
their ability to resist the eff  ects of neu-
trophil-derived reactive oxygen species 
and antimicrobial peptides (  19, 20  ). The 
neutrophils, on the other hand, undergo 
rapid lysis after uptake of these strains 
(  Fig. 1  ) (  15, 21  ).   The ability of   S. aureus   
to survive after phagocytosis has lead 
some to suggest that neutrophils could 
be a vector for disseminating bacteria 
(  22, 23  ).   S. aureus   can also persist inside 
macrophages for several days, ultimately 
causing the death of the cells in a pro-
cess that depends on Hla (  24  ). 
  Because uptake does not necessarily 
correlate with the killing of   S. aureus  , 
high titers of anticapsule antibodies, 
which facilitate uptake, may not protect 
against disease. This notion is not new, 
as it has long been known that virtually 
all humans have circulating antistaphy-
lococcal antibody, and yet some still 
become infected (  25  ). The idea that anti-
bodies against the bacterial capsule may 
not provide protection was borne out in 
two unsuccessful phase III clinical trials 
designed to test the effi   cacy of active im-
munization against the   S. aureus   antigens 
CP5, CP8, and ClfA (  26  ). 
  Hla, a pore-forming cytolytic toxin 
that assembles as a heptameric      -barrel 
structure in the plasma membrane of 
susceptible cells, is arguably the most 
widely studied   S. aureus   toxin (for review 
see reference   27  ). The toxin is known 
to cause destruction of a wide-range 
of host cells, including erythrocytes, 
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Vaccine-induced protection correlated 
directly with reduced infl  ammation and 
less severe destruction of lung tissue. Pas-
sive immunization with Hla antibody 
24 h before intranasal challenge with 
  S. aureus   also protected animals against 
an otherwise lethal intranasal challenge 
with CA-MRSA or an antibiotic-sen-
sitive   S. aureus   strain (  7  ). 
  Antibodies against Hla also pro-
tected human lung epithelial cells from 
  S. aureus    –  induced lysis (  7  ). Although these 
results indicate that Hla contributes to 
lung tissue destruction, it is not yet clear 
whether the animals  ’   death resulted from 
direct destruction of lung cells by the 
toxin, from an excessive infl  ammatory 
response, or from both. Passive transfer 
of Hla antibodies signifi  cantly reduced 
circulating levels of interleukin 1    , a cyto-
kine known to accompany acute lung 
injury. Therefore, it is reasonable to con-
clude that the infl  ammatory  response 
may contribute to Hla-mediated lung 
damage (  Fig. 2  ).   
  A role for other toxins? 
  There has been considerable debate 
about whether another   S. aureus   toxin, 
PVL, is essential for CA-MRSA viru-
lence. In their report, Wardenburg and 
Schneewind found that, unlike anti-
bodies specifi  c for Hla, antibodies spe-
cifi  c for PVL did not protect mice against 
  S. aureus   pneumonia (  7  ). This fi  nding was 
wconsistent with an earlier study by this 
group, which also suggested that PVL is 
not required for CA-MRSA  –  induced 
pneumonia in mice (  29  ). 
  This result appears to confl  ict  with 
earlier data suggesting an essential role for 
PVL (  30  ). But that study relied on labora-
tory strains of   S. aureus   that overexpressed 
PVL, thus clouding the physiological 
signifi  cance of these fi  ndings. Indeed, 
studies conducted using animal models 
of CA-MRSA disease have unanimously 
suggested that PVL is dispensable for 
bacterial virulence ( 21, 29 ). Recent work 
has, however, highlighted the potential 
importance of other virulence factors in 
CA-MRSA disease (  28, 29  ). 
  Bacterial toxins as vaccine targets 
  There are numerous examples of success-
ful vaccination against bacterial toxins, 
  A vaccine approach for treatment of 
  S. aureus   pneumonia 
  Until now, vaccination against Hla has 
not been tested in an   S. aureus   pneumo-
nia model. In this issue, Wardenburg and 
Schneewind show that immunization 
against Hla prevents   S. aureus   pneumo-
nia (  7  ). The authors fi  rst show that the 
severity of lung disease in mice corre-
lates with the levels of Hla produced by 
a particular  S. aureus   isolate ( 7  ). These fi  nd-
ings are consistent with a recent study 
from the same group demonstrating that 
Hla is important for the pathogenesis of 
CA-MRSA pneumonia (  29  ). 
  In the new study, mice were immu-
nized with a nonpore-forming Hla vari-
ant, Hla  H135L  , and challenged intranasally 
3 wk later, a protocol that typically in-
duces lethal pneumonia (  29  ). Immuni-
zation with Hla  H135L   protected 90 –  100% 
mice against all   S. aureus   strains tested (  7  ). 
epithelial cells, fi  broblasts, and monocytes. 
Hla gained notoriety in 1928 when it 
was implicated in the deaths of 12 
Australian children who had received a 
diphtheria toxoid vaccine that was later 
found to be contaminated with an Hla-
producing  S. aureus   strain ( 27  ). Although 
anti-Hla antibody therapy was studied 
intensively, interest in this approach 
waned during the antibiotic era.   S. aureus   
encodes numerous other extracellular 
cytolytic toxins, including      -hemolysin, 
     -hemolysin, Panton-Valentine leuko-
cidin (PVL), leukocidin D/E, a leuko-
cidin homologue (LukM/F     -PV), and the 
newly described phenol-soluble modulin-
like peptides (  28  ). The relative contribu-
tion of Hla to human disease as com      pared 
with these other virulence factors is 
not known, in part because suscepti-
bility to Hla varies among diff  erent ani-
mal species. 
    Figure 1.         Potential pitfall of   S. aureus   vaccines designed to enhance bacterial uptake 
by neutrophils.    S. aureus   is opsonized by bacteria-specific antibody and serum complement, 
which promote rapid binding and uptake of the bacteria by neutrophils. After uptake,   S. aureus  
uses multiple mechanisms to survive and cause the death of the cell, allowing the escape of 
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